Company intelligence / Profile preview

Genome Therapeutics Corporation

Waltham, MA, United Statessec.gov ↗

Ownership: Private
Development stage: Phase 3

Overview

In its final years as Genome Therapeutics Corp., the company commercialized FACTIVE® (gemifloxacin mesylate) tablets—an FDA-approved fluoroquinolone antibiotic for community-acquired pneumonia and acute bacterial exacerbation of chronic bronchitis. It also advanced Ramoplanin into Phase II/III trials targeting serious hospital infections. The company pioneered genome sequencing efforts including the first commercial genome sequence of H. pylori.

Therapeutic areas: PulmonologyGastroenterologyInfectious Diseases
Industry: Biotech

Drug pipeline

1 asset

ramoplanin

Phase 3

Indications: Bloodstream infections, Clostridium difficile-associated diarrhea

Partnerships

Astra ABSchering-PloughAbbott LaboratoriesImmuno-Cor

Beyond the preview

Go deeper on Genome Therapeutics Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genome Therapeutics Corporation.

Explore the full profile